Positive results from the HIMALAYA phase III trial showed a single priming dose of tremelimumab added to Imfinzi (durvalumab) demonstrated a statistically significant and clinically meaningful improvement in overall survival versus Nexavar (sorafenib) as a first-line treatment for patients with unresectable hepatocellular carcinoma who had not received prior systemic therapy and were not eligible for localized treatment.
In 1974, The Cancer Letter published a story listing seven proposed “laws” postulated by of one of oncology’s wise men, Emil J Freireich (The Cancer Letter, May 14, 1976).
A University of Toronto-led study found that only 59% of oncology clinical trials studied provided adequately-defined rules for censoring.
Sharon Wilks joined NEXT Oncology’s phase I clinical investigation team, bringing more than 30 years of research and clinical experience to the practice.
The investigational oral selective estrogen receptor degrader elacestrant significantly decreased the risk of death or disease progression and increased progression-free survival compared with standard-of-care endocrine therapy for postmenopausal patients with estrogen receptor (ER)-positive/HER2-negative metastatic breast cancers that progressed on prior endocrine and targeted therapies, according to results from the phase III EMERALD trial.
Among patients with hormone receptor-positive breast cancer treated with an aromatase inhibitor plus Ibrance (palbociclib), those who displayed a rising ESR1 mutation detected in their blood before disease progression doubled their median progression-free survival following a switch to Faslodex (fulvestrant) plus Ibrance, according to results from the phase III PADA-1 clinical trial.
Results from the registration-enabling EXPLORER and PATHFINDER trials of Ayvakit (avapritinib) highlighted its robust efficacy and safety datasets in advanced systemic mastocytosis.
The Bristol Myers Squibb Foundation, together with its partners, National Medical Fellowships and the American Association for Cancer Research, selected 52 physicians for its Diversity in Clinical Trials Career Development Program. These early-stage investigators are the first of 250 community-oriented clinical trialists who will be trained through the program by 2027.
Emergent public-private partnerships (PPPs) have risen to the occasion to streamline and coordinate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. With these monumental efforts have come important public discussions about equitable access and representation in clinical trials (CTs).
NEXT Oncology entered into an agreement with the Quirónsalud Group to open two new phase I clinical trial centers in Spain.
